EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

BAP1 as a predictive biomarker of therapeutic response to oncolytic vaccinia virus for metastatic renal cell carcinoma therapy

Jee Soo Park, Won Sik Jang, Myung Eun Lee, Jongchan Kim, Keunhee Oh, Namhee Lee, Won Sik Ham

Cancer Immunology, Immunotherapy · 2025

DOI: 10.1007/s00262-025-04139-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Jee Soo Park und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Oncolytic Virotherapy, Ubiquitin Thiolesterase, Kidney Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korean Urological Oncology Society, Patient-Centered Clinical Research Coordinating Center, Korea Health Industry Development Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The therapeutic efficacy of oncolytic vaccinia virus (JX-594) has been demonstrated in metastatic clear cell renal cell carcinoma (ccRCC); however, only selected patients respond, and there are no predictive biomarkers for therapeutic response. We aimed to identify predictive biomarkers for JX-594 treatment and elucidate the underlying mechanisms.

Methods

Four cell line-derived xenograft (CDX) models were developed using representative ccRCC cell lines harboring common mutations. Tumors were subcutaneously implanted into the right flank of BALB/c nude mice. Mice were treated with vehicle or JX-594 via intratumoral injection on days 0, 3, and 6, and tumor growth was evaluated. Therapeutic efficacies of JX-594 and a STING agonist were compared in the BAP1-mutant (769-P) CDX model.

Results

All four CDX models showed significant tumor shrinkage following JX-594 treatment versus control. JX-594 exhibited greater efficacy than the STING agonist in BAP1-deficient xenografts. The BAP1 mutation was associated with rapid tumor progression and a stronger response to JX-594. JX-594 induced IFN-β expression through IRF7-dependent signaling in BAP1-deficient cells, bypassing impaired STING–IRF3 signaling.

Conclusions

We identified BAP1 as a potential predictive biomarker for JX-594 treatment and explored its underlying mechanisms. However, given that the study used immunodeficient models, the findings reflect tumor-intrinsic interferon responses and require further validation in immunocompetent models to assess immune microenvironment modulation and clinical relevance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellOncolytic VirotherapyUbiquitin ThiolesteraseKidney NeoplasmsTumor Suppressor ProteinsVaccinia virusOncolytic VirusesBiomarkers, TumorAnimalsHumansMiceXenograft Model Antitumor AssaysMice, NudeMice, Inbred BALB CCell Line, TumorFemale

Stichwörter der Autor:innen

BAP1Oncolytic vaccinia virusPexastimogene devacirepvec (pexa-vec)Predictive biomarkerRenal cell carcinoma

Substanzen

Ubiquitin ThiolesteraseTumor Suppressor ProteinsBAP1 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.
  • Department of Urology, Yongin Severance Hospital, Yonsei University Health System, Yongin, Republic of Korea.
  • Research Center, SillaJen, Inc., Seoul, Republic of Korea.
  • Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea. uroham@yuhs.ac.

Förderung

  • Korean Urological Oncology Society
  • Patient-Centered Clinical Research Coordinating Center
  • Korea Health Industry Development Institute
  • National Research Foundation of Korea
  • Yonsei University College of Medicine

Zitieren

APA

Park, J. S., Jang, W. S., Lee, M. E., Kim, J., Oh, K., Lee, N., & Ham, W. S. (2025). BAP1 as a predictive biomarker of therapeutic response to oncolytic vaccinia virus for metastatic renal cell carcinoma therapy. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04139-4

Vancouver

Park JS, Jang WS, Lee ME, Kim J, Oh K, Lee N, et al. BAP1 as a predictive biomarker of therapeutic response to oncolytic vaccinia virus for metastatic renal cell carcinoma therapy. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04139-4

BibTeX
@article{Park2025,
  author = {Park, Jee Soo and Jang, Won Sik and Lee, Myung Eun and Kim, Jongchan and Oh, Keunhee and Lee, Namhee and Ham, Won Sik},
  title = {BAP1 as a predictive biomarker of therapeutic response to oncolytic vaccinia virus for metastatic renal cell carcinoma therapy},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  doi = {10.1007/s00262-025-04139-4}
}
Kostenlos starten →